s6y

Theriva Biologics, Inc.

Ticker
TOVX
CIK
894158
Industry
Pharmaceutical Preparations
Formerly
Synthetic Biologics, Inc., ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD PHARMACEUTICALS INC, SHEFFIELD MEDICAL TECHNOLOGIES INC

Financials 108

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 108 financials filings

News 367

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 367 news filings

Ownership 232

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. SC 13G Major Shareholders
  10. SC 13G Major Shareholders

All 232 ownership filings

Prospectus 115

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. S-3 Registration statement for specified transactions by certain issuers
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 115 prospectus filings

Proxies 79

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 79 proxies filings

Other 138

  1. ARS Annual report to security holders
  2. EFFECT Notice of Effectiveness
  3. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  4. SCHEDULE 13G
  5. D Exempt (Private) Offering
  6. SCHEDULE 13G/A
  7. SCHEDULE 13G
  8. ARS Annual report to security holders
  9. EFFECT Notice of Effectiveness
  10. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

All 138 other filings